Rockwell Medical (RMTI)
(Delayed Data from NSDQ)
$2.17 USD
+0.03 (1.40%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
RMTI 2.17 +0.03(1.40%)
Will RMTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RMTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMTI
Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Lags Revenue Estimates
RMTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
Other News for RMTI
Rockwell Medical, Inc. 2024 Q2 - Results - Earnings Call Presentation
Maxim Group Reaffirms Their Buy Rating on Rockwell Med (RMTI)
Rockwell Medical, Inc. (RMTI) Q2 2024 Earnings Call Transcript
Rockwell Medical: Q2 Earnings Snapshot
Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024